Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/29625602/ below:

Aggressive primary treatments with favourable 5-year survival for screen-interval breast cancers

Affiliations

• ¹ Poitou-Charentes General Cancer Registry, Poitiers University Hospital, University of Poitiers, Poitiers, France. gautier.defossez@univ-poitiers.fr.
• ² INSERM, CIC 1402, Poitiers, France. gautier.defossez@univ-poitiers.fr.
• ³ Poitou-Charentes General Cancer Registry, Poitiers University Hospital, University of Poitiers, Poitiers, France.
• ⁴ INSERM, CIC 1402, Poitiers, France.

• PMID: 29625602
• PMCID: PMC5889614
• DOI: 10.1186/s12885-018-4319-4

Item in Clipboard

Gautier Defossez et al. BMC Cancer. 2018.

• ¹ Poitou-Charentes General Cancer Registry, Poitiers University Hospital, University of Poitiers, Poitiers, France. gautier.defossez@univ-poitiers.fr.
• ² INSERM, CIC 1402, Poitiers, France. gautier.defossez@univ-poitiers.fr.
• ³ Poitou-Charentes General Cancer Registry, Poitiers University Hospital, University of Poitiers, Poitiers, France.
• ⁴ INSERM, CIC 1402, Poitiers, France.

• PMID: 29625602
• PMCID: PMC5889614
• DOI: 10.1186/s12885-018-4319-4

Item in Clipboard

Background: To assess the impact of the participation in screening programme according to the mode of detection on the early diagnosis, treatment, and specific survival outcomes in women with breast cancer.

Methods: Women diagnosed with invasive breast cancer in Poitou-Charentes region (France) between 2008 and 2009 were classified into three groups, using data linkage of cancer registry, vital statistics and French organized screening programme: the screening programme (SP), interval cancer (IC), and non-screening programme detected cancer (NSP) groups. Specific survival rates were analysed using the Kaplan-Meier method and Cox proportional hazard models.

Results: Among 1613 patients, 65.7% (n = 1059) participated in a screening programme. The interval cancer rate was 17.1% (n = 181). Tumours in the IC group were diagnosed at a more advanced stage, i.e. with further regional lymph node metastasis or local spread, than those in the SP group (p < 0.001), but with significantly fewer metastases at diagnosis than in the NSP group (p < 0.001). ICs underwent more aggressive primary treatments than the two other groups, with 28% of radical mastectomy and 67% undergoing chemotherapy. The five-year survival rate for IC group were 92.0% (95% CI, 89.9-94.0%).

Conclusions: Interval cancers had more aggressive features than screen-detected cancers but were diagnosed at a less advanced stage compared to non-screen detected cancers. Despite having cancers missed by the screening programme, women who participate in the screening process seem to benefit from early treatment. These results must be confirmed with long-term follow-up.

Keywords: Breast neoplasms; Cancer registry; Data linkage; Interval Cancer; Mass screening; Survival; Treatment.

PubMed Disclaimer

This study was approved by the French regulatory authorities (the “Comité Consultatif sur le Traitement de l’Information en matière de Recherche dans le Domaine de la Santé” and the “Commission Nationale Informatique et Libertés”, authorisation number 907303). According to French law, patients were informed of their data registration and given the right to deny access or to rectify their personal data.

Not applicable.

The authors declare that they have no competing interests.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Inclusion of patients according to…

Inclusion of patients according to the mode of detection. * According to the…

Inclusion of patients according to the mode of detection. * According to the Breast Imaging-Reporting And Data System (BI-RADS) classification of the American College of Radiology

Disease-specific survival probability of patients…

Disease-specific survival probability of patients with invasive breast cancer according to the mode…

Disease-specific survival probability of patients with invasive breast cancer according to the mode of detection

• Screening status, tumour subtype, and breast cancer survival: a national population-based analysis.

  O'Brien KM, Mooney T, Fitzpatrick P, Sharp L. O'Brien KM, et al. Breast Cancer Res Treat. 2018 Nov;172(1):133-142. doi: 10.1007/s10549-018-4877-9. Epub 2018 Jul 13. Breast Cancer Res Treat. 2018. PMID: 30006795

• Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.

  Shen Y, Yang Y, Inoue LY, Munsell MF, Miller AB, Berry DA. Shen Y, et al. J Natl Cancer Inst. 2005 Aug 17;97(16):1195-203. doi: 10.1093/jnci/dji239. J Natl Cancer Inst. 2005. PMID: 16106024

• Clinicopathological differences between interval and screen-detected breast cancers diagnosed within a screening programme in Northern Portugal.

  José Bento M, Gonçalves G, Aguiar A, Antunes L, Veloso V, Rodrigues V. José Bento M, et al. J Med Screen. 2014 Jun;21(2):104-9. doi: 10.1177/0969141314534406. Epub 2014 May 6. J Med Screen. 2014. PMID: 24803482

• Favourable prognostic factors of subsequent screen-detected breast cancers among women aged 50-69.

  Chiarelli AM, Edwards SA, Sheppard AJ, Mirea L, Chong N, Paszat L, Shumak RS, Oʼmalley FP; Breast Screening Study Group. Chiarelli AM, et al. Eur J Cancer Prev. 2012 Nov;21(6):499-506. doi: 10.1097/CEJ.0b013e328350b0f4. Eur J Cancer Prev. 2012. PMID: 22273849 Review.

• Interval breast cancers are not biologically distinct--just more difficult to diagnose.

  Koivunen D, Zhang X, Blackwell C, Adelstein E, Humphrey L. Koivunen D, et al. Am J Surg. 1994 Dec;168(6):538-42. doi: 10.1016/s0002-9610(05)80118-7. Am J Surg. 1994. PMID: 7977992 Review.

• Breast cancer screening: Impact on care pathways.

  Lefeuvre D, Catajar N, Le Bihan Benjamin C, Ifrah N, De Bels F, Viguier J, Bousquet PJ. Lefeuvre D, et al. Cancer Med. 2019 Jul;8(8):4070-4078. doi: 10.1002/cam4.2283. Epub 2019 Jun 6. Cancer Med. 2019. PMID: 31172693 Free PMC article.

• Risk factors for interval breast cancer: insights from a decade of a mammography screening program.

  Subelack J, Morant R, Blum M, Eichenberger A, Geissler A, Ehlig D. Subelack J, et al. Breast Cancer Res Treat. 2025 May;211(1):23-33. doi: 10.1007/s10549-025-07619-4. Epub 2025 Feb 12. Breast Cancer Res Treat. 2025. PMID: 39934544 Free PMC article.

• Interval breast cancer is associated with other types of tumors.

  Grassmann F, He W, Eriksson M, Gabrielson M, Hall P, Czene K. Grassmann F, et al. Nat Commun. 2019 Oct 22;10(1):4648. doi: 10.1038/s41467-019-12652-1. Nat Commun. 2019. PMID: 31641120 Free PMC article.

• Radiological features of screening-detected and interval breast cancers and subsequent survival in Eastern Finnish women.

  Nykänen A, Sudah M, Masarwah A, Vanninen R, Okuma H. Nykänen A, et al. Sci Rep. 2024 May 1;14(1):10001. doi: 10.1038/s41598-024-60740-0. Sci Rep. 2024. PMID: 38693256 Free PMC article.

• Evaluation of a population-based breast cancer screening in North China.

  Wu S, Liang D, Shi J, Li D, Liu Y, Hao Y, Shi M, Du X, He Y. Wu S, et al. J Cancer Res Clin Oncol. 2023 Sep;149(12):10119-10130. doi: 10.1007/s00432-023-04905-w. Epub 2023 Jun 2. J Cancer Res Clin Oncol. 2023. PMID: 37266660 Free PMC article.

1. 1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386. doi: 10.1002/ijc.29210. - DOI - PubMed
2. 1. Sant M, Allemani C, Capocaccia R, Hakulinen T, Aareleid T, Coebergh JW, et al. Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. Int J Cancer. 2003;106:416–422. doi: 10.1002/ijc.11226. - DOI - PubMed
3. 1. Altobelli E, Lattanzi A. Breast cancer in European Union: an update of screening programmes as of march 2014 (review) Int J Oncol. 2014;45:1785–1792. doi: 10.3892/ijo.2014.2632. - DOI - PMC - PubMed
4. 1. Lauby-Secretan B, Loomis D, Straif K. Breast-Cancer screening--viewpoint of the IARC working group. N Engl J Med. 2015;373:1479. - PubMed
5. 1. Paci E, EUROSCREEN Working Group Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen. 2012;19(Suppl 1):5–13. doi: 10.1258/jms.2012.012077. - DOI - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3